OKYO Pharma Ltd (OKYO) Actualités

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference

LONDON and NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference

LONDON and NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

OK-101 is the first drug candidate to enroll patients specifically diagnosed with Neuropathic Corneal Pain...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain

Neuropathic corneal pain (NCP) is listed in the National Organization for Rare Disorders (NORD) as an orphan...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

OKYO Pharma Announces Chairman Acquires Shares

LONDON and NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

OKYO Pharma Announces Chairman Acquires Shares

LONDON and NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease

LONDON and NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]